Sugi Predict

Sugi Predict / Targets / SRSF9

SRSF9

Serine/arginine-rich splicing factor 9 · Q13242 · SRSF9 on Sugi Atlas →

0 patent compounds predicted against SRSF9, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SRSF9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer PHASE2COMPLETED
SRSF2 Gene Mutation in Patients With t-MDS/AML nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs nanUNKNOWN
Research for Individualized Therapeutics in Rare Genetic Disease nanENROLLING_BY_INVITATION
Mechanisms of Cell Death in Spinal Muscular Atrophy nanCOMPLETED
Molecular Disease Profile of Hematological Malignancies nanUNKNOWN
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping nanUNKNOWN
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders nanCOMPLETED
RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2 nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) nanCOMPLETED
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Improving Genetic Counseling for Patients With Spina Bifida Using Next Generation Sequencing nanCOMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SRSF9 binder may also engage these)

ProteinNameSimilarity
Q9D0B0 — 1.000 Q9D0B0 →
Q5PPI1 — 1.000 Q5PPI1 →
SRSF1 Serine/arginine-rich splicing factor 1 1.000 landscape →
Q3YLA6 — 0.999 Q3YLA6 →
Q5R7H2 — 0.994 Q5R7H2 →
Q6NYA0 — 0.994 Q6NYA0 →
Q0VCY7 — 0.994 Q0VCY7 →
Q9ZPX8 — 0.993 Q9ZPX8 →
Q6DII2 — 0.993 Q6DII2 →
Q7SXP4 — 0.992 Q7SXP4 →
F4JHI7 — 0.987 F4JHI7 →
O22315 — 0.987 O22315 →
Q6PDM2 — 0.987 Q6PDM2 →
Q9NEW6 — 0.984 Q9NEW6 →
Q9XFR5 — 0.984 Q9XFR5 →
RBM3 RNA-binding protein 3 0.982 landscape →
A2RVS6 — 0.981 A2RVS6 →
Q925G0 — 0.979 Q925G0 →
Q23120 — 0.979 Q23120 →
P25555 — 0.979 P25555 →
P92964 — 0.977 P92964 →
P92966 — 0.977 P92966 →
P78814 — 0.976 P78814 →
P84104 — 0.975 P84104 →
SRSF3 Serine/arginine-rich splicing factor 3 0.975 landscape →
P38922 — 0.975 P38922 →
Q6K4N0 — 0.974 Q6K4N0 →
P92965 — 0.974 P92965 →
Q5ZML3 — 0.973 Q5ZML3 →
O89086 — 0.973 O89086 →